Evolving Standard Of Care May Be To Blame For Phase III Failure Of Ulimorelin, Tranzyme Says
This article was originally published in Pharmaceutical Approvals Monthly
An evolution in the methods hospitals use to speed gastrointestinal recovery after abdominal surgery may have undercut the Phase III efficacy results for the intravenous ghrelin agonist, which was shown to be no better than placebo in the first of two pivotal trials to report.
You may also be interested in...
Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.